





Imaging risk in pulmonary arterial hypertension

Roberto Badagliacca and Carmine Dario Vizza 👨

Affiliation: Dept of Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy.

Correspondence: Roberto Badagliacca, Dept of Cardiovascular and Respiratory Science, I School of Medicine, Sapienza University of Rome, Policlinico Umberto I, Viale del Policlinico 155 - 00161 Rome, Italy. E-mail: roberto.badagliacca@uniroma1.it

@ERSpublications

Risk assessment is essential in PAH to optimise treatment decisions aiming to slow disease progression. Imaging of the RV matters in the assessment of these patients, and needs to be seriously considered in the elaboration of more performant tools. https://bit.ly/3ibbo9F

Cite this article as: Badagliacca R, Vizza CD. Imaging risk in pulmonary arterial hypertension. Eur Respir J 2020; 56: 2002313 [https://doi.org/10.1183/13993003.02313-2020].

This single-page version can be shared freely online.

Pulmonary arterial hypertension (PAH) is a Janus-faced entity with, on one side, the pulmonary circulation and, on the other side, the right ventricle (RV) [1]. While the disease process is turned on at the site of the pulmonary resistive vessels, the patient symptomatology and prognosis are largely determined by RV structure and function adaptation to increased afterload [2, 3]. Yet, this important cardiac aspect of PAH pathophysiology remains insufficiently recognised. The study by Ghio *et al.* [4], in the present issue of the *European Respiratory Journal*, is therefore a welcome step forward.

Copyright ©ERS 2020